Using platelet-rich plasma and excimer light to treat stable acral vitiligo

Platelet-rich Plasma Intradermal Injection in Addition to 308 nm Excimer Light in the Treatment of Stable Acral Vitiligo: A Prospective Randomized Placebo-controlled Study

This study is testing if combining platelet-rich plasma injections with excimer light therapy can help adults with stable acral vitiligo see better results than just using the light therapy alone.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 20 (estimated)
• Ages: 18 Years to 65 Years
• Sex: All
• Sponsor: Huashan Hospital (Academic / other)
• Locations: 1 site (Shanghai, Shanghai)
• Trial ID: NCT06394349 on ClinicalTrials.gov

What this trial studies

This clinical trial aims to evaluate the effectiveness of platelet-rich plasma (PRP) combined with 308 nm excimer light therapy in treating stable acral vitiligo in adults. Participants will receive either PRP injections along with excimer light therapy or a placebo with the same light therapy over a period of six months. The study will assess the efficacy of this combined treatment compared to excimer light therapy alone and monitor any potential side effects associated with PRP injections. Participants will maintain a diary to track their symptoms and side effects throughout the trial.

Who should consider this trial

Good fit: Ideal candidates are adults with stable non-segmental vitiligo affecting less than 10% of their body surface area, specifically on the hands and fingers.

Not a fit: Patients who have received systemic treatments or phototherapy for vitiligo within the last year or those with certain skin conditions may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new effective option for patients suffering from stable acral vitiligo.

How similar studies have performed: While the use of PRP in dermatological conditions is gaining interest, this specific combination of PRP and excimer light for acral vitiligo is relatively novel and has not been extensively tested in prior studies.

Eligibility criteria

Inclusion Criteria:

* Patients with non-segmental vitiligo stable for more than half a year;
* At least 1 separate stable lesion on each of the dorsum of the right and left hands, proximal fingers, distal fingers and palms;
* The area of white spots is less than 10 % of the total body surface area and more than 1 % of the total body surface area;
* Those who have not received systemic treatment of vitiligo and phototherapy or related treatments within 1 month ≥ 1 year without significant efficacy;
* Voluntary signing of informed consent.

Exclusion Criteria:

* Pregnant and lactating women;
* Those who have used glucocorticoids or other immunosuppressants in the last 3 months;
* Suffering from haematological disorders such as coagulation abnormalities and thrombocytopoietic disorders;
* Those who are allergic to ultraviolet light and photosensitive treatment;
* Scar constitution;
* Those with current or previous history of skin cancer or family history of skin cancer;
* Those with infectious diseases such as HIV, syphilis, hepatitis B or C;
* Those with other serious systemic diseases;
* Patients who, in the judgement of the investigator, are not suitable for inclusion in this trial.

Where this trial is running

Shanghai, Shanghai

• Huashan Hospital — Shanghai, Shanghai, China (Recruiting)

Study contacts

• Principal investigator: Yijian Zhu, M.D. — Huashan Hospital
• Study coordinator: Yijian Zhu, M.D.

Conditions Vitiligo; Acral vitiligo; Platelet-rich plasma; 308 nm excimer light